The Government has published its long-awaited response to the Accelerated Access Review.
Adopting the review’s recommendation, the headline announcement is that from April 2018 there will be a new Accelerated Access Pathway, which means that a few products each year will receive ‘breakthrough designation’ which will fast track process by up to four years. In return, the government emphasises that life sciences firms will be expected to deliver additional value to taxpayers.
The government is hoping to provide:
- £86 m to help innovators access the market
- £6 m to support clinicians to use new treatments
- £40 m to encourage grassroots adoption of new medtech
Sir Andrew Witty, former chief executive of GSK, will chair the Accelerated Access Collaborative, which will make decisions on which products are to be fast tracked.
Click here to read MAP’s summary of the response.